Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanomaAlice Indini, Michele Del Vecchio, Lorenza Di Guardo et al.|Journal of Cancer Research and Clinical Oncology|2018Cited by 200
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A. Ascierto, Paola Queirolo, Ester Simeone et al.|Journal of Translational Medicine|2014Cited by 164
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaMichele Del Vecchio, Michele Maio, Lorenza Di Guardo et al.|European Journal of Cancer|2013Cited by 157
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaMichele Maio, Paolo A. Ascierto, Riccardo Danielli et al.|Annals of Oncology|2013Cited by 141
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Vanna Chiarion‐Sileni, Francesco Spagnolo et al.|Journal of Neuro-Oncology|2014Cited by 119